VJOncology is committed to improving our service to you

Share this video  

VJOncology is committed to improving our service to you

ASCO 2022 | Bevacizumab for the treatment of patients with ovarian cancer exhibiting poor chemosensitivity

Benoit You, MD, PhD, Centre Hospitalier Lyon-Sud, Saint-Genis-Laval, France, discusses bevacizumab in the treatment landscape of patients with ovarian cancer. As indicated by the data from the Phase III GOG-0218 (NCT00262847) trial which evaluated carboplatin and paclitaxel with or without bevacizumab in patient with stage III or stage IV ovarian, epithelial, primary peritoneal, or fallopian tube cancer, bevacizumab should be prioritized in patients with poor chemosensitivity. According to the results of GOG-0218, which showed a benefit of bevacizumab in patients who were poorly chemosensitive, this can increase the efficacy of chemotherapy and improve the overall-survival of this patient population. This interview took place at the American Society of Clinical Oncology (ASCO) 2022 Annual Meeting in Chicago, IL.

Sign-up for our Newsletter!

Keep up to date with all the latest news with our monthly newsletter